Effect of Platelet Injection on Burn Scar

Phase 3

• Conditions: Burn scar.; Scar conditions and fibrosis of skin; L90.5

• Registration Number: IRCT20231209060308N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Presence of at least two atrophic burn scars anywhere on the body in a symmetrical pattern.
Age between 18-60 years.
Both male and female genders are included in this study.

Exclusion Criteria

Patients with underlying conditions such as diabetes, blood clotting disorders, and immunodeficiency disorders.
Pregnant patients or those planning to become pregnant.
Patients diagnosed with any malignancy.
Smokers with more than one pack of cigarettes per day (Heavy Smokers)
Patients who have received another treatment for their scars within the 3-month period prior to the commencement of the intervention, which may have led to collagen stimulation.
Patients who do not have the mental capacity to provide consent for participation in the study or to respond to researchers' inquiries.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient and Observer Scar Assessment Scale (POSAS) points. Timepoint: In the first visit, the initial treatment session, one month, and three months after the last treatment session. Method of measurement: Patient and Observer Scar Assessment Scale (POSAS).;Changes in skin tone evenness. Timepoint: In the initial treatment session, one month, and three months after the last treatment session. Method of measurement: VisioFace.;Local inflammatory or irritating adverse events. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hemosiderin staining. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Herpes. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hypersensitivity reactions. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.